drugset
drugset / Trial / NCT04591808

Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia

NCT04591808 ↗

Phase 3 Terminated 146 enrolled Servier ADIR, a Servier Group company · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to demonstrate the superiority of atorvastatin/perindopril fixed dose combination (FDC) S05167 as compared to atorvastatin reference drug alone or perindopril drug alone on systolic blood pressure decrease and LDL cholesterol decrease respectively in patients presenting with hypertension and dyslipidemia after 8 weeks of treatment.

Timeline

Start
2021-09-09
Primary completion
2022-04-08
Completion
2022-04-08

Outcome

Outcome not reported

Stopped (Business): “for strategic reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 40 mg —
Subject Perindopril Small molecule 10 mg —

Indications

hyperlipidemia hypertensive disorder